New, even more effective HPV vaccine in sight

September 11, 2013, Medical University of Vienna
New, even more effective HPV vaccine in sight

A recently published paper by the Department of Immunodermatology at the Medical University of Vienna has unveiled a second-generation prophylactic HPV vaccine. In future, this will not only protect against the majority of genital high and low-risk types, but also the types that are responsible for the development of skin warts.

The results of the pre-clinical study, which raises hopes for the future development of a broadly effective vaccine against the Human Papillomavirus (HPV), have recently been published in the highly respected magazine Journal of Investigative Dermatology. The study was carried out by Christina Schellenbacher and a team led by Reinhard Kirnbauer from the Department of Immunodermatology at the MedUni Vienna (headed by Georg Stingl), with the collaboration of working groups from the Vienna University of Veterinary Medicine, the University of Malmö and the Johns Hopkins University (in Baltimore, USA). The next stage involves the vaccine's evaluation in clinical trials.

Unlike with the vaccines that have been available previously, which contain two to four antigens, the researchers adopted a different approach: they put together an individual, new antigen (RG1-VLP) from the 's main capsid protein L1 and auxiliary L2. In laboratory studies, this vaccine demonstrated significantly broader effectiveness against high and low-risk types of HPV compared to the vaccines that are available currently.

New vaccine also effective against hand and foot warts

Unless previous vaccines, the new also protects for the first time against cutaneous, or skin-based, types of HPV. These types of HPV cause hand and foot warts as well as flat warts, primarily among children, but also in adults. These skin changes can cause significant problems, especially for immunosuppressed patients.

Vaccination makes sense for children

The results of the study also raise the prospect of administering the vaccine to children. According to the researchers, this would help effectively prevent the development of during childhood and later infections with genital viruses.

Reinhard Kirnbauer, who is also already the inventor of the existing HPV16 vaccine and therefore the key element of the new vaccine, also highlights two further advantages: "The vaccine has been formulated as a singular antigen (RG1-VLP), offering a prospective economic advantage compared to the existing licensed vaccines and a nine-in-one vaccine that is currently undergoing clinical trials. HPV-VLP vaccines also have an excellent safety profile, which means we are now keen to push ahead with the evaluation of the in clinical studies."

Explore further: 1 in 5 boys got HPV shot in first year recommended

More information: Schellenbacher, C. et al. Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses, Journal of Investigative Dermatology. DOI: 10.1038/jid.2013.253

Related Stories

1 in 5 boys got HPV shot in first year recommended

August 29, 2013
A new report offers a first look at how many boys are getting shots designed to protect girls from cervical cancer. Health officials say the number getting vaccinated so far is a good start.

HPV vaccination to provide even more protection in future against infections

April 17, 2013
At present over one hundred strains of the human papillomavirus (HPV) are known, fourteen of which can trigger cancer. The HPV vaccinations currently in use provide protection from 70 percent of these cancers. "With the next ...

Hidden strains of HPV found in 'virus-negative' genital warts

July 11, 2013
There are 170 established HPV types. Cancerous human papillomavirus (HPV) viruses are the main cause of cervical cancer, and are found in close to 100% of cervical tumors.

Significant decline of genital warts in young women

July 20, 2012
(Medical Xpress) -- The incidence of condyloma or genital warts (GW) is significantly declining in young women, according to a novel register study from Karolinska Institutet. The researchers suggest that this recent development ...

How cervical cancer vaccines came to be

January 19, 2013
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.

Report: Teen HPV vaccination rate still lagging

July 25, 2013
(AP)—Disappointed health officials say only about half of teenage girls have gotten a controversial vaccine against cervical cancer—a rate that's changed little in three years.

Recommended for you

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Products of omega-3 fatty acid metabolism may have anticancer effects, study shows

July 13, 2018
A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. The molecules, called endocannabinoids, ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.